Please ensure Javascript is enabled for purposes of website accessibility

Two more patents for NeoDiagnostix

NeoDiagnostix, of Gaithersburg, announced that the U.S. Patent and Trademark Office has granted two patents owned by the company covering the detection of chromosomal abnormalities in cervical samples.  NeoDiagnostix now has four patents regarding methods of detection. Richard M. Pinnola, president and CEO of NeoDiagnostix, said in a statement:  “We believe that our intellectual property assets are a significant value driver for the company, and with a total of four U.S. patents, we feel well-positioned in this area of testing.” The tests are designed to detect genes that would predict cancer.